Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, MaxCyte, Inc. reported revenue of $21M, down 5.7% year over year. Operating margin was -247.6% and net margin -213.0%, on a free-cash-flow margin of -172.6% with capital expenditure at 8.4% of revenue. Every figure is computed directly from MXCT's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $21M | -247.6% | -213.0% |
| FY2024 | $22M | -230.5% | -184.8% |
| FY2023 | $19M | -247.7% | -194.5% |
| FY2022 | $29M | -95.2% | -82.0% |
| FY2021 | $22M | -84.3% | -88.5% |
How does MXCT compare against its actual peer set?
The full CompsDesk Peer Benchmark Pack: up to 14 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, provenance for every number, board-ready PDF + CSV. One-off $249.
Related in the same sector: AACG · ABSI · ACCS · ACM · ADUS · AGL
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.